Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient mice.
Saved in:
| Title: | Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient mice. |
|---|---|
| Authors: | Cook AK; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Lin B; Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Song Y; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Biochemistry and Molecular Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Greathouse KM; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Kaplelach AK; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Love ML; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Davis SE; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Stoll AC; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Hall JA; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Hakim AR; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Hel JF; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Vollmer GA; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Howard AC; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Cooper NH; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Manuel PN; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Eberhardt JM; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Miller CR; Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Harms AS; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Herskowitz JH; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Rizzardi LF; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Biochemistry and Molecular Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Arrant AE; Killion Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: andrewarrant@uabmc.edu. |
| Source: | Neurobiology of disease [Neurobiol Dis] 2026 Sep; Vol. 227, pp. 107475. Date of Electronic Publication: 2026 Jun 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Academic Press Country of Publication: United States NLM ID: 9500169 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-953X (Electronic) Linking ISSN: 09699961 NLM ISO Abbreviation: Neurobiol Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
